278 related articles for article (PubMed ID: 25694444)
1. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
[TBL] [Abstract][Full Text] [Related]
2. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
[TBL] [Abstract][Full Text] [Related]
3. Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells.
Rohrer Bley C; Orlowski K; Furmanova P; McSheehy PM; Pruschy M
Lung Cancer; 2011 Sep; 73(3):294-301. PubMed ID: 21333376
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
5. Role of the microenvironment for radiosensitization by patupilone.
Bley CR; Jochum W; Orlowski K; Furmanova P; Vuong V; McSheehy PM; Pruschy M
Clin Cancer Res; 2009 Feb; 15(4):1335-42. PubMed ID: 19228735
[TBL] [Abstract][Full Text] [Related]
6. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
7. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
9. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
10. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts.
Zhang M; Tao W; Pan S; Sun X; Jiang H
Anticancer Drugs; 2009 Jun; 20(5):355-63. PubMed ID: 19318912
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
12. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
13. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
14. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
[TBL] [Abstract][Full Text] [Related]
15. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
16. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
18. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
19. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
20. The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion.
Furmanova-Hollenstein P; Broggini-Tenzer A; Eggel M; Millard AL; Pruschy M
Radiat Oncol; 2013 Apr; 8():105. PubMed ID: 23631818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
